Enhanced Activation of the S1PR2-IL-1β-Src-BDNF-TrkB Pathway Mediates Neuroinflammation in the Hippocampus and Cognitive Impairment in Hyperammonemic Rats.

BDNF cognitive impairment glutamate receptor hepatic encephalopathy neuroinflammation sphingosine-1-phosphate

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
08 Dec 2023
Historique:
received: 10 11 2023
revised: 04 12 2023
accepted: 06 12 2023
medline: 23 12 2023
pubmed: 23 12 2023
entrez: 23 12 2023
Statut: epublish

Résumé

Hyperammonemia contributes to hepatic encephalopathy. In hyperammonemic rats, cognitive function is impaired by altered glutamatergic neurotransmission induced by neuroinflammation. The underlying mechanisms remain unclear. Enhanced sphingosine-1-phosphate receptor 2 (S1PR2) activation in the cerebellum of hyperammonemic rats contributes to neuroinflammation. in In hyperammonemic rats, we assessed if blocking S1PR2 reduced hippocampal neuroinflammation and reversed cognitive impairment and if the signaling pathways were involved. S1PR2 was blocked with intracerebral JTE-013, and cognitive function was evaluated. The signaling pathways inducing neuroinflammation and altered glutamate receptors were analyzed in hippocampal slices. JTE-013 improved cognitive function in the hyperammonemic rats, and hyperammonemia increased S1P. This increased IL-1β, which enhanced Src activity, increased CCL2, activated microglia and increased the membrane expression of the NMDA receptor subunit GLUN2B. This increased p38-MAPK activity, which altered the membrane expression of AMPA receptor subunits and increased BDNF, which activated the TrkB → PI3K → Akt → CREB pathway, inducing sustained neuroinflammation. This report unveils key pathways involved in the induction and maintenance of neuroinflammation in the hippocampus of hyperammonemic rats and supports S1PR2 as a therapeutic target for cognitive impairment.

Identifiants

pubmed: 38139078
pii: ijms242417251
doi: 10.3390/ijms242417251
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital
ID : PROMETEOII/2018/051
Organisme : Ministerio de Ciencia e Innovación
ID : PID2020-113388RB-I00

Auteurs

María Sancho-Alonso (M)

Laboratory of Neurobiology, Centro de Investigación Príncipe Felipe, 46012 Valencia, Spain.
Institute of Biomedical Research of Barcelona (IIBB), Spanish National Research Council (CSIC), 08036 Barcelona, Spain.
Systems Neuropharmacology Research Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Biomedical Research Networking Center for Mental Health (CIBERSAM), Institute of Health Carlos III (ISCIII), 28029 Madrid, Spain.

Yaiza M Arenas (YM)

Laboratory of Neurobiology, Centro de Investigación Príncipe Felipe, 46012 Valencia, Spain.

Paula Izquierdo-Altarejos (P)

Laboratory of Neurobiology, Centro de Investigación Príncipe Felipe, 46012 Valencia, Spain.

Mar Martinez-Garcia (M)

Laboratory of Neurobiology, Centro de Investigación Príncipe Felipe, 46012 Valencia, Spain.

Marta Llansola (M)

Laboratory of Neurobiology, Centro de Investigación Príncipe Felipe, 46012 Valencia, Spain.

Vicente Felipo (V)

Laboratory of Neurobiology, Centro de Investigación Príncipe Felipe, 46012 Valencia, Spain.

Classifications MeSH